Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

myRocky vs Primary Clinic (Direct GLP)

myRocky
Graded #487

Lower grade

vs+17.300000000000004
Primary Clinic (Direct GLP)
Graded #145

Higher grade

The verdict

Primary Clinic (Direct GLP) takes it — 68.7/100 to 51.4/100.

Primary Clinic (Direct GLP) grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Primary Clinic (Direct GLP) is a Direct Primary Care membership rather than the usual direct-to-consumer GLP-1 marketplace.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valuePrimary Clinic (Direct GLP) +44
34
78
Dose & formulationPrimary Clinic (Direct GLP) +1
53
54
Clinical oversightPrimary Clinic (Direct GLP) +11
64
75
Labs & monitoringPrimary Clinic (Direct GLP) +24
52
76
FulfillmentPrimary Clinic (Direct GLP) +3
70
73
Contract termsEven
41
41
myRocky · left barPrimary Clinic (Direct GLP) · right bar

The numbers

MetricmyRockyPrimary Clinic (Direct GLP)
WeighScore51.4/10068.7/100
GradeCC
Scorecard rank#487#145
SemaglutideNot disclosed$65/mo (0.25 mg dose, promotional rate, compounded)
TirzepatideNot disclosed$110/mo (2.5 mg dose, promotional rate, compounded)
CoverageCoverage not published10 states
Brand-name accessYesCompounded only
Oral / sublingualInjection onlyInjection only
myRocky

Graded #487 · C

Strengths

  • Brand-name FDA-approved GLP-1s (Ozempic, Mounjaro, Wegovy) on one platform — no compounded-product risk
  • LegitScript Approved
  • 42-state coverage with an 8-state expansion roadmap published
  • Multi-product platform for patients managing GLP-1 plus sexual health, hair loss, or mental health on one subscription

Where it loses points

  • Expensive stacked fees: $99 consult + $99/mo program fee + ~$1,409/mo medication = ~$1,508/mo
  • Canadian incorporation (Rocky Health Inc., Mississauga, ON) — verify your state's prescriber holds an active US license
  • Listed pharmacy is a Canadian community pharmacy; US-fulfillment supply chain not transparent
  • Brand-only — no compounded option for cost-sensitive patients
  • $1,409/mo Ozempic is near retail; compare NovoCare ($349/mo Wegovy pen) or LillyDirect ($449–$699/mo Zepbound)

Strengths

  • Direct Primary Care model integrates GLP-1 with continuous primary care — unlike most direct-to-consumer platforms
  • GLP-1 at wholesale cost with no markup — semaglutide from $65/mo, tirzepatide from $110/mo (members only)
  • Unlimited primary care visits, direct text access, and same-day care bundled in the $89/mo membership
  • Routine labs and thousands of medications included in membership — no surprise bills
  • Per-dose pricing shown publicly for all 8 dose tiers of both semaglutide and tirzepatide

Where it loses points

  • 10 states only (WA, NM, AZ, UT, FL, DC, KS, OK, VA, GA) — limited vs 50-state platforms
  • Membership required to access wholesale pricing — $89/mo adds ~$1,068/yr in fixed cost
  • 503A pharmacy partners not named
  • LegitScript certification not mentioned on the site
  • Medical director and corporate legal entity not disclosed

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard